Integra LifeSciences Holdings Corporation — Q3 2014 Form 10-Q
Business context and reporting period
Integra develops and sells medical technology products across neurosurgery, orthopedics, spine, reconstructive surgery, wound care, and surgical instruments. The filing covers the three and nine months ended September 30, 2014. Comparative 2013 amounts were retrospectively adjusted for the medical device excise tax accounting change and certain segment reclassifications.
Key financial metrics
| Metric | Q3 2014 | Q3 2013 | 9M 2014 | 9M 2013 |
|---|---|---|---|---|
| Revenue | $229.7 million | $213.2 million | $676.1 million | $615.4 million |
| Gross margin | 62.6% | 61.7% | 62.2% | 60.5% |
| Operating income (loss) | $17.7 million | $(31.1) million | $38.9 million | $(27.8) million |
| Net income (loss) | $9.8 million | $(30.3) million | $16.8 million | $(34.8) million |
| Diluted EPS | $0.30 | $(1.09) | $0.51 | $(1.25) |
| Operating cash flow | Not separately reported | Not separately reported | $58.7 million | $41.6 million |
At September 30, 2014, cash and cash equivalents were $140.2 million, versus $120.6 million at December 31, 2013. Working capital was $432.5 million, compared with $401.8 million at year-end 2013. Total debt consisted primarily of $411.9 million under the Senior Credit Facility and $211.1 million carrying value of the 2016 convertible notes. Approximately $488.1 million remained available under the credit facility, and the company was in compliance with its covenants.
Net cash used in investing activities was $264.5 million, including $235.0 million for the Confluent Surgical acquisition and $29.5 million of capital expenditures. Net cash provided by financing activities was $231.0 million, primarily from increased credit-facility borrowings. Inventory increased to $230.5 million from $206.9 million at December 31, 2013.
Material changes versus the prior comparable period
- Revenue increased 7.7% in the third quarter and 9.9% for the first nine months. U.S. Neurosurgery revenue grew 38% in the quarter and 41% year to date, primarily reflecting the acquired DuraSeal products.
- U.S. Extremities revenue increased 15% in the quarter and 10% year to date. International revenue increased 6% and 9%, respectively.
- U.S. Instruments revenue declined 7% in the quarter and 5% year to date, while U.S. Spine and Other revenue declined 11% and 5%, respectively.
- Gross margin improved due to product mix, increased sales of higher-margin DuraSeal, skin and wound products, and reduced recall and remediation costs.
- Results improved substantially because 2013 included a $46.7 million goodwill impairment charge related to U.S. Spine and costs associated with the recall of collagen-based products. No comparable goodwill impairment was recorded in 2014.
- Selling, general and administrative expense increased to $109.9 million in the quarter and $333.5 million year to date, reflecting DuraSeal-related selling costs, acquisition integration, ERP depreciation, consulting, headcount, and severance costs.
Guidance, outlook, risks, and unusual items
- Management expected full-year 2014 gross margin of approximately 62%, research and development expense of approximately 6% of revenue, selling, general and administrative expense of approximately 47% to 49% of revenue, and an effective tax rate of approximately 23% to 24%.
- Management expected 2014 capital expenditures of $40 million to $45 million and approximately $6 million of annual incremental ERP depreciation over the system’s useful life.
- The January 2014 Confluent Surgical acquisition had an aggregate purchase price of $255.9 million, including $20.9 million of acquisition-date fair value for contingent consideration. The purchase-price allocation remained preliminary.
- On October 27, 2014, Integra completed the approximately $60 million MicroFrance acquisition from Medtronic; purchase-price allocation had not yet been completed.
- On November 3, 2014, Integra announced a proposed 2015 spin-off of its Spine business and a realignment of the remaining operations into Specialty Surgical Solutions and Orthopedics and Tissue Technologies. Completion was subject to board approval, tax treatment, SEC registration effectiveness, and other conditions. One-time separation costs were expected.
- The FDA completed its September 2014 reinspection of the Añasco, Puerto Rico facility and reported that prior warning-letter issues had been addressed, with no additional observations. The Andover, England remediation program remained subject to continued regulatory oversight.
- Special charges totaled $17.7 million in the third quarter and $51.1 million year to date, including ERP implementation, structural optimization, severance, discontinued product lines, acquisition-related costs, remediation, and non-cash convertible-debt interest.
- Management identified risks from medical-device regulation, product quality and recalls, foreign currency, variable interest rates, dependence on manufacturing and suppliers, integration and separation activities, and the potential volatility of contingent consideration and tax matters.
Facts investors should verify
- Whether DuraSeal and other Confluent Surgical products sustain the reported neurosurgery growth and margins after the sales-force transition.
- Progress, costs, tax treatment, timing, and final terms of the proposed Spine spin-off.
- The final purchase-price allocation and operating contribution of Confluent Surgical and MicroFrance.
- Debt reduction capacity, the 2016 convertible-note maturity, credit-facility covenants, and exposure to higher interest rates.
- Whether the reported improvement in profitability is sustainable after excluding the prior-year goodwill impairment and recall-related costs.
- FDA follow-up, product-quality compliance, future remediation costs, and any effect on product approvals or sales.
- Execution of the ERP implementation and the resulting recurring depreciation and integration expenses.